RxDoctor Payments Data

Anaida Nadal Torres

Rheumatology · Guayama, PRNPI 1598868531

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (35.5%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 63.9% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2020 at $4,052 and has fallen 78.1% since, to $887 in 2025.

$15,884in general payments, 2019–2025

Across 271 payments — averaging $58.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$10K
  • AbbVie$1K
  • Novartis$1K
  • Amgen$966
  • AstraZeneca$528
  • GSK$408
  • plus $1K from 14 others

What the payments were for

  • Consulting fees$5,22533%
  • Speaking & faculty fees$4,82830%
  • Food & beverage$5,63335%
  • Education$1981%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,884 in reported general payments places this provider in the 85th percentile of 88 rheumatology providers in Puerto Rico.

See all rheumatology providers in Puerto Rico

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab319$2,191,457
Orencia ClickjectAbatacept232$1,315,011
RinvoqUpadacitinib198$1,279,154
Enbrel SureclickEtanercept101$757,283
Xeljanz XrTofacitinib Citrate95$550,116
Skyrizi PenRisankizumab-Rzaa18$375,148
KevzaraSarilumab79$344,055
Cosentyx Sensoready PenSecukinumab40$296,992
Cosentyx Sensoready (2 Pens)Secukinumab29$210,599
BenlystaBelimumab42$194,862
Taltz AutoinjectorIxekizumab26$187,633
Humira(Cf)Adalimumab25$170,990
SimponiGolimumab27$162,301
ProliaDenosumab84$148,916
Actemra ActpenTocilizumab40$94,207

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira(Cf)$1,385$1,450,144223 claims
SanofiKevzara$38$344,05579 claims
GSKBenlysta$408$194,86242 claims
Johnson & JohnsonSimponi$192$162,30127 claims
AmgenProlia$966$148,91684 claims
E.r. Squibb & Sons, L.L.C.Orencia$10,156$85,99315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 88 rheumatology providers in Puerto Rico.

Other rheumatology in Guayama

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →